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ABSTRACT:
Trastuzumab-refractory breast cancer stem cells (CSCs) could explain the high rate of 
primary resistance to single-agent trastuzumab in HER2 gene-amplified breast cancer 
patients. The identification of agents with strong selective toxicity for trastuzumab-
resistant breast CSCs may have tremendous relevance for how HER2+ breast cancer 
patients should be treated. Using the human breast cancer cell line JIMT-1, which 
was established from the pleural metastasis of a patient who was clinically resistant 
to trastuzumab ab initio, we examined whether preferential killing of the putative 
CD44+CD24-/low  breast  CSC  population  might  be  sufficient  to  overcome  primary 
resistance to trastuzumab in vivo. Because recent studies have shown that the anti-
diabetic biguanide metformin can exert antitumor effects by targeted killing of CSC-
like cells, we explored whether metformin’s ability to preferentially kill breast cancer 
initiating CD44+CD24-/low cells may have the potential to sensitize JIMT-1 xenograft 
mouse models to trastuzumab. Upon isolation for breast cancer initiating CD44+CD24-/
low cells by employing magnetic activated cell sorting, we observed the kinetics of 
metformin-induced killing drastically varied among CSC and non-CSC subpopulations. 
Metformin’s  cell  killing  effect  increased  dramatically  by  more  than  10-fold  in 
CD44+CD24-/low breast CSC cells compared to non-CD44+CD24-/low immunophenotypes. 
While seven-weeks treatment length with trastuzumab likewise failed to reduce tumor 
growth of JIMT-1 xenografts, systemic treatment with metformin as single agent 
resulted in a significant two-fold reduction in tumor volume. When trastuzumab was 
combined with concurrent metformin, tumor volume decreased sharply by more than 
four-fold. Given that metformin-induced preferential killing of breast cancer initiating 
CD44+CD24-/low subpopulations is sufficient to overcome in vivo primary resistance 
to trastuzumab, the incorporation of metformin into trastuzumab-based regimens 
may provide a valuable strategy for treatment of HER2+ breast cancer patients. 
INTRODUCTION
De novo (i. e. primary) resistance to the monoclonal 
antibody trastuzumab (Herceptin) remains a prevalent 
challenge in the treatment of breast cancer patients whose 
tumors overexpress the human epidermal growth factor 2 
(HER2) [1]. Evidence is mounting that the CD44+CD24-/
low cell subpopulation, which is enriched with potential 
breast cancer stem cells (CSCs), could explain clinical 
resistance to HER2-targeted therapies [1-3]. Therefore, Oncotarget 2012; 3:  395-398 396 www.impactjournals.com/oncotarget
future clinical trials should involve the integration of novel 
anti-breast cancer stem cells approaches to prevent and 
overcome the inherent unresponsiveness to trastuzumab 
across clinically important subgroups of HER2-positive 
breast cancer patients. Although in vitro studies have 
recently suggested that the anti-diabetic drug metformin 
can  efficiently  eliminate  treatment-resistant  stem/
progenitor cell populations in heterogeneous breast cancer 
populations [4-6], it remained to be evaluated whether 
systemic metformin might overcome primary resistance 
to trastuzumab in HER2-gene amplified human breast 
cancer xenografts. Here we explored for the first time the 
in vivo sensitizing efficacy of metformin on trastuzumab 
therapy by using xenografts of the human breast cancer 
cell line JIMT-1, which was established from the pleural 
metastasis of a patient who was clinically resistant to 
trastuzumab ab initio [7]. The JIMT-1 model is unique 
because of displaying at the same time several co-existing 
mechanisms of resistance to trastuzumab present at 
variable levels in other breast cancer cell lines, including 
moderate expression levels of HER2 (despite HER2 gene 
amplification), low expression of PTEN (phosphatase and 
tensin homolog), an activating mutation of the PIK3CA 
gene,  high  expression  of  NRG1  (neuregulin-1),  and 
enhanced expression of mesenchymal markers, including a 
naturally enriched subpopulation of breast cancer initiating 
CD44+CD24-/low CSC-like cells [2, 8-10]. 
RESULTS AND DISCUSSION
Metformin preferentially kills breast cancer 
initiating CD44+CD24-/low cells
We  first  examined  whether  breast  cancer 
initiating CD44+CD24-/low and non-CD44+CD24-/low cell 
subpopulations from the trastuzumab-refractory JIMT-1 
cell line exhibited differential sensitivities to the growth 
inhibitory effects of metformin. We employed MTT-based 
cell viability assays to compare the degree of sensitivity 
to metformin of parental JIMT-1 cells and that of JIMT-
1  cell  subpopulations  isolated  and  purified  for  breast 
cancer initiating CD44+CD24-/low and non-CD44+CD24-/low 
immunophenotypes by employing magnetic activated cell 
sorting (MACS; Fig. 1A, top panels). Cells were treated 
side-by-side on the following sorting day with graded 
concentrations of metformin for five days. While unsorted 
JIMT-1, CD44+CD24-/low, and CD44+CD24+ populations 
all showed an inhibitory response to metformin that 
augmented with the increase in metformin concentration 
(Fig. 1A, bottom left), each separate cell population 
differed in their extend of cytotoxic response to metformin. 
The breast cancer initiating CD44+CD24-/low subpopulation 
was significantly more sensitive than was the parental or 
CD44+CD24+ populations. CD44+CD24-/low cells had an 
estimated IC50 value of 1±0.2 mmol/L metformin whereas 
that in the corresponding non-CD44+CD24-/low population 
was 11±2 mmol/L metformin (Fig. 1A, bottom right). 
The IC50 of metformin in the unsorted JIMT-1 parental 
population was 8±2 mmol/L (Fig. 1A, bottom  right). 
These findings, altogether, confirmed that the breast cancer 
initiating subpopulation within a heterogeneous population 
of trastuzumab-refractory, HER2-positive breast cancer 
cells notably exhibit greater sensitivity to the growth-
inhibitory effects of metformin. Indeed, the growth of 
the breast cancer initiating CD44+CD24-/low population 
was more significantly affected by metformin at all tested 
concentrations. Because it has been shown that gradual 
loss of stem cell markers takes place in cells growing 
as a monolayer, these data may further underestimate 
hypersensitivity of the breast cancer initiating 
CD44+CD24-/low cells to metformin. Indeed, JIMT-1 
cells sorted for the CD44+CD24-/low immunophenotype 
repopulated all the parental cell fractions after few days in 
monolayer culture (data not shown). 
Systemic metformin inhibits tumor growth in 
trastuzumab-refractory breast cancer xenografts
The effects of metformin and trastuzumab alone 
and in combination on tumor growth were next studied 
in vivo using a JIMT-1 xenograft animal model (Fig. 
1B). Compared to the control group after seven weeks 
of treatment (940±170 mm3), the trastuzumab-treated 
group  likewise  failed  to  exhibit  significant  reductions 
in mean tumor size (891±135 mm3). Compared to the 
mean xenograft tumor size in both the control and the 
trastuzumab group, the mean tumor size in the metformin 
group was significantly smaller (390±64 mm3), which 
confirmed that the inhibitory effect of metformin at the 
tested concentration (250 mg/kg/day) was notably stronger 
than that of trastuzumab (5 mg/kg/week) on JIMT-1 tumor 
growth. When the two drugs were combined, the xenograft 
tumor size (213±75 mm3) was smaller than those of the 
groups treated with trastuzumab or metformin alone, 
indicating that the combination of the drugs was much 
more effective at reducing tumor volume. Consequently, 
the days required for four-fold increase in tumor volume 
was 27±5 after treatment with trastuzumab whereas more 
than 50 days were required after the combined treatment 
with trastuzumab and metformin (Fig. 1B). No significant 
difference in body weight was observed in xenograft 
tumor-bearing mice between the treatment groups (data 
not shown). 
Our  current  findings  reveal  that:  a.)  Metformin 
as single agent is active against JIMT-1-derived tumor 
xenografts with primary resistance to trastuzumab; b.) 
metformin’s ability to distinctively kill breast cancer 
initiating CD44+CD24-/low mesenchymal subpopulations 
is sufficient to overcome in vivo primary resistance to Oncotarget 2012; 3:  395-398 397 www.impactjournals.com/oncotarget
Figure 1: A. Top. CD44 and CD24 expression patterns in CD44+CD24-/low and CD44+CD24+ subpopulations of JIMT-1 sorted by 
sequential sorting (depletion followed by positive selection) using MACS MicroBeads (MACS® Technology). Enrichment of target 
cells by magnetic MicroBeads was carried out according to the manufacturer’s (Milteny Biotec, Bergisch Gladbach, Germany) protocol. 
CD44+CD24-/low were isolated from the parental JIMT-1 cell line by firstly depleting CD24+ cells using the CD24 MicroBead Kit and 
then positively selected for CD44 using the CD44 MicroBeads. Cells were fluorescently stained with combinations of fluorochrome-
conjugated monoclonal antibodies obtained from BD Biosciences (San Diego, CA, USA) against human CD44 (FITC; cat.#555478) and 
CD24 (PE; cat.#555428) or their respective isotype controls. Representative expression (n=5) in pre-sorted and post-sorted JIMT-1 cells 
is shown. Bottom. Parental JIMT-1 cells and cells sorted for BCSC+ CD44+CD24-/low and non-BCSC-CD44+CD24+ markers were treated 
simultaneously with increasing concentrations of metformin for 5 days. Cell viability was determined using a standard colorimetric MTT 
(3-4, 5-dimethylthiazol-2-yl-2, 5-diphenyl-tetrazolium bromide) reduction assay. For each treatment, cell viability was evaluated as a 
percentage using the following equation: (OD570 of treated sample/OD570 of untreated sample) × 100. Cell sensitivity to metformin was 
expressed in terms of the concentration of drug required to decrease by 50% cell viability (IC50 value). Since the percentage of control 
absorbance was considered to be the surviving fraction of cells, the IC50 values were defined as the concentration of agents that produced 
50% reduction in control absorbance. B. Tumor xenografts were established by subcutaneous injection of 5 x 106 JIMT-1 cells suspended 
in 100 μl of culture medium into the flank of female athymic nude mice (four to five weeks old, 23 to 25 g; Harlan Laboratories –France-).   
Animals were randomized into four groups with five mice in each group: control (vehicles), trastuzumab, metformin, and trastuzumab + 
Metformin. Trastuzumab (5 mg/kg) was given intraperitoneally (i.p.) once per week. Both the “metformin group” and the “trastuzumab + 
metformin group” received daily a single i.p. injection of metformin (250 mg/kg). Mice were weighed once per week after dosing, tumors 
were measured daily with electronic callipers, and tumor volumes were calculated using the following formula: volume (mm3) = length 
x width2 x 0.5. Figure shows mean tumor volumes (±SD) of JIMT-1 xenograft-bearing nude mice following injection with trastuzumab, 
metformin, and trastuzumab + metformin until seven weeks.
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trastuzumab in HER2-gene amplified breast tumors. A 
combination of trastuzumab and metformin may provide 
a valuable strategy for treatment of HER2-overexpressing 
breast cancer, and a phase II trial recently has opened 
in  Spain  to  evaluate  the  efficacy  of  trastuzumab  plus 
metformin as neo-adjuvant therapy for patients with 
HER2-positive breast cancer [11]. 
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